Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Guiding transplant decisions in multiple myeloma with MRD

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Addressing the rise of multiple myeloma in Rwanda

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia